Search Results - "Plested EL"

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.

Authors: Kelly E Greenland M de Whalley PCS et al.

Corporate Authors: Kelly E Greenland M de Whalley PCS et al.

Source: The Journal of infection [J Infect] 2023 Sep; Vol. 87 (3), pp. 230-241. Date of Electronic Publication: 2023 Jun 17.

Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Authors: Shaw RH Greenland M Stuart ASV et al.

Corporate Authors: Shaw RH Greenland M Stuart ASV et al.

Source: The Journal of infection [J Infect] 2023 Jun; Vol. 86 (6), pp. 574-583. Date of Electronic Publication: 2023 Apr 06.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Authors: Shaw RH Liu X Stuart ASV et al.

Corporate Authors: Shaw RH Liu X Stuart ASV et al.

Source: The Lancet. Respiratory medicine [Lancet Respir Med] 2022 Nov; Vol. 10 (11), pp. 1049-1060. Date of Electronic Publication: 2022 Jun 09.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Authors: Stuart ASV Shaw RH Liu X et al.

Corporate Authors: Stuart ASV Shaw RH Liu X et al.

Source: Lancet (London, England) [Lancet] 2022 Jan 01; Vol. 399 (10319), pp. 36-49. Date of Electronic Publication: 2021 Dec 06.

Publication Type: Clinical Trial, Phase II; Equivalence Trial; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Authors: Liu X Shaw RH Stuart ASV et al.

Corporate Authors: Liu X Shaw RH Stuart ASV et al.

Source: Lancet (London, England) [Lancet] 2021 Sep 04; Vol. 398 (10303), pp. 856-869. Date of Electronic Publication: 2021 Aug 06.

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE